A former GlaxoSmithKline (gsk) senior political lobbyist is to join
Oxfam, the charity which has fiercely criticised the pharmaceutical
industry over the high price of Aids drugs.
David Earnshaw quit gsk in February, soon after it was created from the
merger of Glaxo Wellcome - one of the world's leading producers of Aids
treatment products - and SmithKline Beecham (SB).
He had previously been SB head of European government affairs.
He takes up the newly-created role of EU representative for Oxfam
International next month and is already urging his former employers to
speed up a reduction in drugs prices.
He said: 'The pharmaceutical industry in general - and that includes
gsk - needs to be doing more.
'The pharmaceutical companies need to act. If they don't, governments
will do it for them.'
However, he denies that his latest role is a 'poacher turned gamekeeper'
move.'I'm not interested in sides or conflict. I want to see the NGOs,
governments and the companies working together to help solve this
problem,' he said.
Earnshaw, who will be based in Brussels and is likely to head a
three-strong team, reports to Oxfam advocacy director Phil Twyford, who
is based in Washington.
Josephine Wood, previously SB EU policy adviser, has taken over from
Earnshaw to head lobbying work at gsk's Brussels office.
Earnshaw is one of a raft of former SB senior staff to have left the
Last month, gsk announced that James Hill, SB corporate affairs chief,
will leave within the next three months.
Lynne Smith, former SB director and V-P of corporate communications
(Europe and international) left last month.